Grupo para la caracterización molecular de las neoplasias hematológicas
Ankara University
Ankara, TurquíaPublicaciones en colaboración con investigadores/as de Ankara University (6)
2021
-
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 801-812
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2019
-
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
The Lancet Infectious Diseases, Vol. 19, Núm. 9, pp. 988-1000
2018
-
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, Núm. 10, pp. e401-e419
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362